The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and Obesity.
Semaglutide and tirzepatide are showing up in more research outside of diabetes and weight management. A new analysis puts these peptides in the spotlight for people with knee osteoarthritis who also have obesity. The big question: do these research compounds make sense as an investment for this group?
Ann Intern Med
by Smith KC, Losina E
“The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and Obesity. Smith KC(1), Losina E(1). Author information: (1)Policy and Innovation eValuation in Orthopaedic Treatments (PIVOT) Center and Orthopaedic and Arthritis Center for Outcomes Research (OrACORe), Department of Orthopaedic Surgery, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts. Conflict of interest statement: Disclosures: Disclosure forms are available with the article online.”
Smith and Losina from Harvard Medical School ran the numbers. Their focus: cost-effectiveness. That means not just if semaglutide or tirzepatide work, but whether they deliver enough value for the cost in this specific population.
Key takeaway: Both peptides can drive significant weight loss. That’s already known. But in the context of knee osteoarthritis, shedding pounds can mean less pain and better mobility. The study breaks down how these benefits might translate into real savings on healthcare costs and improved quality of life.
Here’s what stands out:
Weight loss from peptides can reduce knee pain and disability for people with osteoarthritis.
The upfront price of semaglutide and tirzepatide is high, but the long-term benefits might offset those costs—especially if it keeps people out of the operating room and away from expensive treatments.
The researchers use standard cost-effectiveness metrics, tying the numbers to actual outcomes that matter for this group.
For anyone looking at research peptides like semaglutide or tirzepatide for new indications, this kind of analysis is essential. It’s not just about what the peptide does in the lab, but what it means for real-world scenarios where cost and quality of life are front and center.
If you want to source these peptides for your own research, check out our vendor directory. The field keeps moving—don’t get left behind.
Related Reading
Diabetic Retinal Disease Onset and Progression During Established Semaglutide or Tirzepatide Treatment: A Retrospective Comparative Cohort Study With a Descriptive Regional Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Review
News · Food ChemGeneration of cyclic peptides with improved anti-Photoaging activity during the thermal processing of collagen peptides.
News · J Control ReleaseMechanistic benchmarking of SNAC, DDM, and LLC reveals enhancer-dependent pathways for intestinal semaglutide delivery.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.